Canadian Cancer Trials Group Bulletins

Trial Management Group

First US Patient Enrolled to OV.21

The Canadian Cancer Trials Group OV.21 team is pleased to announce that international collaboration with the United States through SWOG has led to patient accrual to the OV.21 trial. Dr. Robert Carolla at Cox Health in Missouri enrolled the study's first US patient on September 19, 2012. We thank our SWOG collaborators for their participation, and are very grateful for the leadership Dr. Deborah Armstrong has provided as the SWOG Study Co-Chair of OV.21.

Canadian Cancer Trials Group OV.21, A Phase II/III Trial of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy, is proceeding well towards its target accrual of 150 patients for the randomized phase II portion of the trial with 120 patients currently enrolled to date, including 8 in September.

Thank you to all our participating sites for your support of this important clinical trial.

If you would like more information about OV.21, please contact Chad Winch, Study Coordinator, at (613) 533-6430 or